Development and Validation of a Prognostic N6-Methyladenosine-Related Immune Gene Signature for Lung Adenocarcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Hutchinson BD, Shroff GS, Truong MT, Ko JP. Spectrum of lung adenocarcinoma. Semin Ultrasound CT MR. 2019;40(3):255–264. doi:10.1053/j.sult.2018.11.009
   PubMed Web of Science ®Google Scholar
• Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9(2):117. doi:10.1038/s41419-017-0063-y
   PubMed Web of Science ®Google Scholar
• Slawinski G, Wrona A, Dabrowska-Kugacka A, Raczak G, Lewicka E. Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: a review. Int J Mol Sci. 2020;21(19):7195. doi:10.3390/ijms21197195
   Web of Science ®Google Scholar
• Zimmermann S, Peters S, Owinokoko T, Gadgeel SM. Immune checkpoint inhibitors in the management of lung cancer. Am Soc Clin Oncol Educ Book. 2018;38:682–695. doi:10.1200/EDBK_201319
   Google Scholar
• Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103. doi:10.1186/s12943-019-1033-z
   PubMed Web of Science ®Google Scholar
• Bi Z, Liu Y, Zhao Y, et al. A dynamic reversible RNA N(6) -methyladenosine modification: current status and perspectives. J Cell Physiol. 2019;234(6):7948–7956. doi:10.1002/jcp.28014
   PubMed Web of Science ®Google Scholar
• Han J, Wang JZ, Yang X, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18(1):110. doi:10.1186/s12943-019-1036-9
   PubMed Web of Science ®Google Scholar
• Guo X, Li K, Jiang W, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Mol Cancer. 2020;19(1):91. doi:10.1186/s12943-020-01158-w
   PubMed Web of Science ®Google Scholar
• Li F, Wang H, Huang H, Zhang L, Wang D, Wan Y. m6A RNA methylation regulators participate in the malignant progression and have clinical prognostic value in lung adenocarcinoma. Front Genet. 2020;11:994. doi:10.3389/fgene.2020.00994
   Web of Science ®Google Scholar
• Zhang X, Zhang S, Yan X, et al. m6A regulator-mediated RNA methylation modification patterns are involved in immune microenvironment regulation of periodontitis. J Cell Mol Med. 2021;25(7):3634–3645. doi:10.1111/jcmm.16469
   Web of Science ®Google Scholar
• Wang L, Hui H, Agrawal K, et al. m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020;39(20):e104514. doi:10.15252/embj.2020104514
   PubMed Web of Science ®Google Scholar
• Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020;117(33):20159–20170. doi:10.1073/pnas.1918986117
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Dickerson HW, Findly RC. Immunity to Ichthyophthirius infections in fish: a synopsis. Dev Comp Immunol. 2014;43(2):290–299. doi:10.1016/j.dci.2013.06.004
   Web of Science ®Google Scholar
• Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014;42(Databaseissue):D199–205. doi:10.1093/nar/gkt1076
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–29. doi:10.1038/75556
   PubMed Web of Science ®Google Scholar
• Otasek D, Morris JH, Boucas J, Pico AR, Demchak B. Cytoscape Automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185. doi:10.1186/s13059-019-1758-4
   PubMed Web of Science ®Google Scholar
• Du J, Hou K, Mi S, et al. Malignant evaluation and clinical prognostic values of m6A RNA methylation regulators in glioblastoma. Front Oncol. 2020;10:208. doi:10.3389/fonc.2020.00208
   Web of Science ®Google Scholar
• Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19(1):53. doi:10.1186/s12943-020-01170-0
   PubMed Web of Science ®Google Scholar
• Braig S, Bosserhoff AK. Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression. Oncogene. 2013;32(7):837–848. doi:10.1038/onc.2012.115
   Web of Science ®Google Scholar
• Forghanifard MM, Naeimi Khorasanizadeh P, Abbaszadegan MR, Javdani Mallak A, Moghbeli M. Role of DIDO1 in progression of esophageal squamous cell carcinoma. J Gastrointest Cancer. 2020;51(1):83–87. doi:10.1007/s12029-019-00212-1
   Web of Science ®Google Scholar
• Forlani G, Shallak M, Celesti F, Accolla RS. Unveiling the hidden treasury: CIITA-driven MHC Class II expression in tumor cells to dig up the relevant repertoire of tumor antigens for optimal stimulation of tumor specific CD4+ T helper cells. Cancers. 2020;12(11):3181. doi:10.3390/cancers12113181
   Web of Science ®Google Scholar
• Accolla RS, Ramia E, Tedeschi A, Forlani G. CIITA-Driven MHC Class II expressing tumor cells as antigen presenting cell performers: toward the construction of an optimal anti-tumor vaccine. Front Immunol. 2019;10:1806. doi:10.3389/fimmu.2019.01806
   Web of Science ®Google Scholar
• Su W, Han HH, Wang Y, et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell. 2019;36(2):139–155 e110. doi:10.1016/j.ccell.2019.06.009
   PubMed Web of Science ®Google Scholar
• Xu J, Zheng H, Yuan S, et al. Overexpression of ANLN in lung adenocarcinoma is associated with metastasis. Thorac Cancer. 2019;10(8):1702–1709. doi:10.1111/1759-7714.13135
   Web of Science ®Google Scholar
• Long X, Zhou W, Wang Y, Liu S. Prognostic significance of ANLN in lung adenocarcinoma. Oncol Lett. 2018;16(2):1835–1840. doi:10.3892/ol.2018.8858
   Web of Science ®Google Scholar
• Ye D, Meurs I, Ohigashi M, et al. Macrophage ABCA5 deficiency influences cellular cholesterol efflux and increases susceptibility to atherosclerosis in female LDLr knockout mice. Biochem Biophys Res Commun. 2010;395(3):387–394. doi:10.1016/j.bbrc.2010.04.027
   Web of Science ®Google Scholar
• Fu Y, Hsiao JH, Paxinos G, Halliday GM, Kim WS. ABCA5 regulates amyloid-beta peptide production and is associated with Alzheimer’s disease neuropathology. J Alzheimers Dis. 2015;43(3):857–869. doi:10.3233/JAD-141320
   Web of Science ®Google Scholar
• Xu F, Cui WQ, Wei Y, et al. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res. 2018;37(1):207. doi:10.1186/s13046-018-0878-0
   PubMed Web of Science ®Google Scholar
• Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol. 2018;9:3176. doi:10.3389/fimmu.2018.03176
   PubMed Web of Science ®Google Scholar
• Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol. 2015;194(7):2985–2991. doi:10.4049/jimmunol.1403134
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239
   PubMed Web of Science ®Google Scholar
• Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24(Suppl 1):S31–S41. doi:10.1634/theoncologist.2019-IO-S1-s05
   PubMed Web of Science ®Google Scholar